1+ day, 3+ hour ago  (624+ words) BioSpace IDEAYA Biosciences Announces ESMO 2026 Presentations for Darovasertib and IDE849 Clinical Programs "We're excited to showcase the breadth of our pipeline progress at this year's ESMO Congress. Additional data from our ongoing trials in both metastatic and neoadjuvant uveal melanoma, namely…...

1+ day, 7+ hour ago  (287+ words) BioSpace BeOne Medicines to Announce Second Quarter 2026 Financial Results on August 5 SAN CARLOS, Calif.--(BUSINESS WIRE)--$ONC #BeOne--BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, will report its second quarter 2026 financial results on Wednesday, August 5, 2026 before…...

1+ day, 5+ hour ago  (243+ words) A new target nomination and a milestone payment mark the next step of the multi-year partnership first announced in December 2023 PARIS & LONDON--(BUSINESS WIRE)--#DrugDiscovery--Aqemia, the drug invention company combining generative AI and quantum-inspired physics to invent small molecule…...

1+ day, 6+ hour ago  (102+ words) BioSpace There’s no doubt that biotech IPOs are back. After a prolonged slowdown in new listings, a rising number of biotechs are once again testing the public markets. But ringing the opening bell is only the beginning. The real question…...

1+ day, 7+ hour ago  (320+ words) GSK will no longer invest in the development of camlipixant in chronic cough after a disappointing late-stage performance. The pharma had been running the Phase 3 CALM-1 and CALM-2 trials, which tested a 52-week and 24-week course of camlipixant, respectively. CALM…...

1+ day, 8+ hour ago  (306+ words) These benefits “strengthen the case” for Insmed’s drug candidate, called treprostinil palmitil inhalation powder (TPIP), “as the best-in-class inhaled prostanoid,” analysts at Guggenheim Partners told investors in a Thursday note. The firm projects peak TPIP sales to top $6 billion across…...

1+ day, 9+ hour ago  (421+ words) Journal articles penned by former FDA officials do not constitute official agency policy, acting director Kyle Diamantas has clarified. Makary and other agency officials, DeGette continued, “made major policy announcements through journal articles, press releases and even podcasts, circumventing FDA’s…...

1+ day, 15+ hour ago  (95+ words) BioSpace GeneDx to Report Second Quarter 2026 Financial Results on Monday, August 3, 2026 GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx (Nasdaq: WGS), the leader in rare disease diagnosis and improving health through the power of genomic data, today announced it will release financial results for…...

1+ day, 18+ hour ago  (176+ words) Advancing rehabilitation innovation through clinical outcomes and the power of direct electric muscle stimulation technology designed to improve strength and build muscle. “Restimulate Health represents a forward-thinking approach to rehabilitation, where technology and clinical expertise come together to improve patient…...

1+ day, 12+ hour ago  (153+ words) Agreement with Kira Pharmaceuticals for exclusive license to KP-301 extends Mirador’s precision medicine strategy into inflammatory vascular disease, with an initial focus on ANCA-associated vasculitis (AAV) KP-301 is engineered to inhibit C5a/C5aR-mediated inflammation through an antibody modality with a potentially…...